Publication
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerLung Adenocarcinomacivic_curation1.00
- drugGefitinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR Exon 19 Deletioncivic_curation1.00
- variantEGFR L858Rcivic_curation1.00
- variantEGFR Rare Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27022112
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR Exon 19 Deletion1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6184A Japanese Phase III clinical study assessed the noninferiority of gefitinib in comparison to erlotinib in 561 patients with postoperative or recurrent stage IIIB/IV lung adenocarcinoma. Patients were… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC | civic |
| EGFR L858R1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID6183In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy … (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC | civic |
| EGFR Mutation1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Does Not Support Reduced Sensitivity | 3 | submitted | EID6187In a Japanese phase III study, lung adenocarcinoma patients with one or more of any mutation in their EGFR gene were treated with either Erlotinib or Gefitinib EGFR tyrosine kinase inhibitors to demon… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC | civic |
| EGFR Rare Mutation1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID6186A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had p… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC | civic |
| EGFR Wildtype1 | ||||||||
| Gefitinib | Lung Adenocarcinoma | Predictive | B | Does Not Support Reduced Sensitivity | 3 | rejected | EID6185In a Japanese Phase III trial, noninferiority of gefitinib in comparison to erlotinib was assessed in lung adenocarcinoma patients with postoperative or recurrent stage IIIb/IV lung adenocarcinoma tre… (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC | civic |